Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01056523 | Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 29 | Jewish General HospitalOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 187 | Bellicum PharmaceuticalsINDUSTRY | 2 | Sep 29, 2023 | clinicaltrials |
| NCT03733249 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study |
| terminated |
| Phase 1 / Phase 2 |
| 187 |
| Bellicum PharmaceuticalsINDUSTRY |
| 1 |
| Sep 26, 2023 |
| clinicaltrials |
| NCT06049667 | A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies | unknown | Phase 1 | 72 | Nanjing Chia-tai Tianqing PharmaceuticalINDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02122081 | Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | completed | Phase 1 | 33 | Sumithira VasuOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 42 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00106600 | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 12 | CTI BioPharmaINDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | terminated | Phase 1 | 8 | Biotheryx, Inc.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | terminated | Phase 1 / Phase 2 | 8 | H Scott BoswellOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT06027853 | Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia | unknown | Phase 1 | 24 | Zhejiang UniversityOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06008405 | Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy | unknown | Phase 1 | 48 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT03390296 | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | withdrawn | Phase 1 / Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Sep 1, 2023 | clinicaltrials |
| NCT04402541 | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 55 | Cleave Therapeutics, Inc.INDUSTRY | 2 | Aug 31, 2023 | clinicaltrials |
| NCT05519527 | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT03531918 | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | completed | Phase 1 / Phase 2 | 66 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04443751 | A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 31 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT00816413 | Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 38 | OncoVerity, Inc.INDUSTRY | 2 | Aug 9, 2023 | clinicaltrials |
| NCT05982756 | Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML | unknown | Phase 1 | 40 | Zhongnan HospitalOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT00516828 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 21 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03867682 | Venetoclax and Lintuzumab-Ac225 in AML Patients | unknown | Phase 1 / Phase 2 | 38 | Actinium PharmaceuticalsINDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05005299 | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation(VICTORY) | unknown | Phase 1 | 18 | Melbourne HealthOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970822 | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML | unknown | Phase 1 | 32 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05226468 | An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia | unknown | Phase 1 | 24 | New Epsilon Innovation LimitedINDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05074550 | Safety Evaluation Study for Patients With Polycythemia Vera | unknown | Phase 1 | 6 | Perseus Proteomics Inc.INDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT02575963 | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 / Phase 2 | 40 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 20, 2023 | clinicaltrials |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | withdrawn | Phase 1 / Phase 2 | 0 | Actinium PharmaceuticalsINDUSTRY | 0 | Jul 20, 2023 | clinicaltrials |
| NCT05949762 | Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly | unknown | Phase 1 / Phase 2 | 45 | ZePing ZhouOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT03566446 | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms | completed | Phase 1 | 10 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04051307 | Dual Vaccine Trial in Myeloproliferative Neoplasms | completed | Phase 1 / Phase 2 | 9 | Inge Marie SvaneOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT02842827 | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | completed | Phase 1 / Phase 2 | 45 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02728050 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 84 | University of WashingtonOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02141828 | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | completed | Phase 1 | 18 | Epizyme, Inc.INDUSTRY | 2 | Jun 18, 2023 | clinicaltrials |
| NCT04679194 | Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT | terminated | Phase 1 | 11 | Mana TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Lynk Pharmaceuticals Co., LtdINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT00641030 | Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 23 | Alice MimsOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02882321 | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05893472 | A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. | unknown | Phase 1 / Phase 2 | 45 | ZePing ZhouOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT05140811 | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 1 / Phase 2 | 126 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03236857 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies | completed | Phase 1 | 143 | AbbVieINDUSTRY | 8 | May 22, 2023 | clinicaltrials |
| NCT05471323 | Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML | unknown | Phase 1 | 36 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05858814 | RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT | unknown | Phase 1 / Phase 2 | 72 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 2, 2023source: clinicaltrials